pretickt

JNJ financials

Johnson & Johnson · end-of-day data as of Oct 16, 2026

Johnson & Johnson
JNJ · $616B
$255.56-2.5%last 60 sessions · close Oct 16, 2026
$181.90$278.4352 weeks
Buy · 23 analystsPT $278.14 +8.8%
  • P/E vs own+33.3%
  • P/E vs sector+37.6%
  • Target upside+8.8%
  • Off 52w high-8.2%
  • Insiders-$64.74M
  • FCF yield—
  • Earnings in96d
  • Trendbullish
  • Sector▲ +16.0%
  • RSI44
  • MA20×50Death 5d ago
  • Volume0.9x
  • Support-1.0%
  • Resistance+4.9%

JNJ reported revenue of $25.4B for the quarter ended Sep 30, 2026 (Q3 FY2026), up 5.9% from a year earlier. It posted diluted EPS of $0.09 and a net margin of 0.8%.

Valuation

  • P/E38.7x
  • P/E vs own+33.3%
  • P/E vs sector+37.6%
  • FCF yield—
  • Market cap$616B

Quarterly results

Q3 FY2026: Revenue +5.9% year over year, operating margin 25.1%.

RevenueFree cash flow
Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$25.4B0.09—73.0%25.1%0.8%
Q2 FY2026Jun 28, 2026$25.31B2.27$3.39B68.2%28.3%21.9%
Q1 FY2026Mar 29, 2026$24.06B2.14$1.47B66.3%26.6%21.8%
Q4 FY2025Dec 28, 2025$24.56B2.10$5.47B67.6%22.8%20.8%
Q3 FY2025Sep 28, 2025$23.99B2.12$8.38B69.6%29.6%21.5%
Q2 FY2025Jun 29, 2025$23.74B2.29$2.48B67.9%28.7%23.3%
Q1 FY2025Mar 30, 2025$21.89B4.54$3.38B66.4%28.8%50.2%
Q4 FY2024Dec 29, 2024$22.52B1.41$4.84B68.3%17.1%15.2%
Q3 FY2024Sep 29, 2024$22.47B1.11$5.71B69.0%23.5%12.0%
Q2 FY2024Jun 30, 2024$22.45B1.93$4.66B69.4%29.7%20.9%
Q1 FY2024Mar 31, 2024$21.38B1.34$2.85B69.6%29.3%15.2%
Q4 FY2023Dec 31, 2023$21.39B1.67$6.27B68.2%21.5%18.9%